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Summary
Two decades after the discovery that 20% of familial amyotrophic lateral sclerosis (ALS) cases 
were linked to mutations in the superoxide dismutase-1 (SOD1) gene, a substantial proportion of 
the remainder of cases of familial ALS have now been traced to an expansion of the intronic 
hexanucleotide repeat sequence in C9orf72. This breakthrough provides an opportunity to re-
evaluate longstanding concepts regarding the cause and natural history of ALS, coming soon after 
the pathological unification of ALS with frontotemporal dementia through a shared pathological 
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signature of cytoplasmic inclusions of the ubiquitinated protein TDP-43. However, with profound 
clinical, prognostic, neuropathological, and now genetic heterogeneity, the concept of ALS as one 
disease appears increasingly untenable. This background calls for the development of a more 
sophisticated taxonomy, and an appreciation of ALS as the breakdown of a wider network rather 
than a discrete vulnerable population of specialised motor neurons. Identification of C9orf72 
repeat expansions in patients without a family history of ALS challenges the traditional division 
between familial and sporadic disease. By contrast, the 90% of apparently sporadic cases and 
incomplete penetrance of several genes linked to familial cases suggest that at least some forms of 
ALS arise from the interplay of multiple genes, poorly understood developmental, environmental, 
and age-related factors, as well as stochastic events.
Introduction
In the autumn of 2011, a monumental discovery changed the way we understand 
amyotrophic lateral sclerosis (ALS). Some 150 years after Charcot provided the first 
description of ALS, a genetic variant was discovered that meant neuroscientists must revisit 
what they knew, or think they knew, about the disorder. Understanding of the cause of this 
therapeutically resistant neurodegenerative disorder has entered a new phase with the 
discovery of linkage to an expansion of an intronic hexanucleotide repeat in the previously 
unknown gene C9orf72. 1 and 2 At the most basic level, this breakthrough provides 
incontrovertible evidence that ALS and frontotemporal dementia are manifestations of a 
clinicopathological spectrum. Most tantalising however is the emergence of a unifying 
pathogenic theme of nuclear protein mishandling in ALS. The apparent RNA binding 
function of the C9orf72 expansion adds to known mutations in other key RNA-processing 
and proteosomal genes linked to ALS, notably the transactive-region DNA-binding protein 
gene TARDBP, 3 the fused in sarcoma gene FUS (also known as translocated in 
liposarcoma, TLS), 4 and the ubiquilin-2 gene UBQLN2, 5 whose proteins are widely 
expressed in human cells, with fundamental physiological roles.
The recent C9orf72 genetic breakthrough further reinforces the concept that ALS 
pathogenesis involves multiple pathways. 6 To date, models of disease have largely centred 
around mutant superoxide dismutase-1 (SOD1), discovered 20 years ago 7 ( figure 1). This 
genetic discovery heralded development of the first animal model of ALS, 8 and the 
availability of a coherent strategy for development of successful therapy. Recent seminal 
findings including a recognition of the importance of TDP-43 deposition in most forms of 
ALS and some forms of frontotemporal dementia, 9 although not in SOD1-related disease, 9 
and the likely role of RNA dysregulation in disease pathogenesis, suggest that translation of 
findings from the SOD1 model to benefit patients living with ALS might be more restricted 
than previously thought. Fundamental aspects of ALS, not least its striking clinical 
heterogeneity, still puzzle clinicians as much now as at the turn of the 20th century and 
remain the subject of debate. The juxtaposition of the new and exciting discovery of a major 
ALS gene, with the emergent problems in the translation of findings from the SOD1 mouse 
model, provided the backdrop to our debate, held as part of the 22nd International 
Symposium on ALS/MND with the specific aim of highlighting areas that with future 
research and prioritisation might lead to the development of treatments. To better guide this 
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therapeutic potential, we considered the clinical scope of ALS, dealing with concepts of 
heterogeneity, while also dissecting arguments concerning focality of disease onset, methods 
to identify patterns of disease spread, and predictors of prognosis, with implications for the 
design of future clinical trials. Recent genetic discoveries and controversies concerning 
heritability and the current models of ALS were incorporated into the discussion, in the 
context of emergent technology, with consideration of priorities for future ALS research.
Has the concept of ALS as one disease become untenable?
From a clinical viewpoint, ALS has been identified by most neurologists as a single entity 
because it characteristically involves a recognised pattern of progressive motor 
neuronopathy, with respiratory failure as the mode of death for most patients. This core 
phenotype is confidently diagnosed by an experienced clinician when progression is rapid, 
although the mean diagnostic delay has stubbornly remained around 1 year from symptom 
onset,10 reflecting the reality of more slowly progressing cases. Although ALS is a 
clinically recognisable condition, there are now strong reasons to consider the classic 
phenotype as a manifestation of a wider aetiopathogenic spectrum.
Although median survival is 3 years from symptom onset, the survival curve for the 
remaining cases tapers out to 20 years or more. Many of the long-term survivors appear to 
have either pure upper motor neuron (termed primary lateral sclerosis) or lower motor 
neuron (termed progressive muscular atrophy) involvement.11 and 12 There is an urgent 
need for reliable subclassification that goes beyond the number of body territories with 
combined clinical upper motor neuron and lower motor neuron signs that underpin the 
current diagnostic criteria.13 There is increasing frustration with this diagnostic framework 
(panel 1), which was developed principally as a research aid, since a substantial proportion 
of patients die with a diagnostic label of “possible ALS”14 even though the clinical 
progression is the same as that of “definite ALS”, but with simply fewer demonstrable upper 
motor neuron signs.
At least 16 genes of major (typically dominant) effect are associated with ALS.15 
Recognisable phenotypes have been reported for some known mutations (table 1), such as 
the SOD1 A4V variant, which produces a rapidly progressive, primarily lower motor neuron 
syndrome; 16 and FUS mutations linked to a juvenile onset, primarily lower motor neuron 
syndrome. 17 However, perhaps the most striking development has been the recent 
recognition of a characteristic phenotype associated with the relatively common C9orf72 
hexanucleotide repeat expansion. Patients with the expansion have a younger age of onset, 
shortened survival, increased rates of cognitive and behavioural impairment, and a strong 
family history of neurodegenerative disease. 18 and 19 Postmortem studies also suggest that 
C9orf72-associated ALS has a different pathological signature to other forms of ALS.
Heterogeneity in neuropathology can also be discerned. Cytoplasmic inclusions of TDP-43 
are found in nearly all autopsied cases of sporadic ALS, and suggest a consistent final 
common pathway. However, such inclusions are notably absent in ALS associated with 
pathogenic mutations of SOD1, 20 and the pathophysiological processes underlying this and 
other abnormal protein aggregation have not been fully elucidated. Expansions of the 
C9orf72 hexanucleotide repeat have a characteristic neuropathological signature, with 
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TDP-43 inclusions but in a different distribution including hippocampal and cerebellar 
regions, and with prominent staining for p62, 21 supporting the view that different primary 
pathophysiological processes have a final common, clinically indistinguishable, endpoint. 
As such, the clinical, pathological, and genetic frameworks traditionally used to explain 
disease heterogeneity remain incomplete, with the corollary that therapeutic interventions 
might need to be tailored across different subgroups of patients, on the basis of the 
prevailing upstream pathological events. Understanding of the physiological roles of 
TDP-43 and C9orf72 will be an essential first step.
Although cognitive and behavioural impairment are now recognised features of ALS, not all 
patients become impaired. Population based studies suggest that 14% of incident cases have 
frontotemporal dementia, and a further 30% have evidence of cognitive impairment, mostly 
but not exclusively in executive dysfunction.22 One of the strongest predictors of cognitive 
or behavioural impairment in ALS is the presence of the C9orf72 repeat expansion. Taken 
together, these findings point perhaps to a distinct phenotype in ALS that includes roughly 
10% of all cases. Patients with early features of executive impairment progress more rapidly, 
whereas those who are cognitively normal at the time of diagnosis have a better prognosis 
and largely do not exhibit features of cognitive decline on serial testing. 23 Furthermore, 
cognitive impairments common to classic ALS have been notably less prevalent in 
progressive muscular atrophy 24 and primary lateral sclerosis. 25 Such observations might 
reflect an increased resistance in some individuals to the penetration of pathology beyond its 
initial clinical focus, with obvious therapeutic value if the biological substrate for this 
resistance could be identified.
Going forward, clinical and genetic studies will require stratification with respect to the 
presence or absence of the C9orf72 expansion and deeper analysis of clinical phenotyping 
and genotyping will clearly be needed, including development of a greater understanding of 
the extreme phenotypes. This process has recently been commenced in several population 
cohorts with C9orf72-related repeats, 18 and has shown distinct clinical and family 
signatures. Separately, studies of the typically more slowly progressive clinical phenotypes 
such as primary lateral sclerosis 26 and progressive muscular atrophy 27 have also been 
undertaken, although major gaps persist in our understanding of molecular changes 
associated with these disorders, in addition to delineation of the extent and timing of upper 
motor neuron versus lower motor neuron involvement. 28 Moreover, there is a particular 
lack of detailed clinicopathological studies in primary lateral sclerosis, 29 regarded by some 
as a separate disease altogether. The development and application of novel in-vivo 
neurophysiological and neuroimaging methods to specific clinical subtypes 30 and 31 have 
the potential to circumvent the end-stage pathology perspective of traditional 
histopathology.
Should ALS even be regarded as a neuromuscular disease?
Many ALS physicians are also specialists in neuromuscular disease, and the characteristic 
presence of progressive muscle wasting, weakness, and fasciculations clearly reflects 
degeneration of anterior horn cells and lower motor neurons. The electromyogram is an 
adjunct to clinical evaluation, and the Awaji criteria, based on features of denervation and 
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reinnervation, have recently been established as a useful diagnostic aid.32 However, as 
originally recognised by Charcot, corticospinal tract involvement is nearly always seen 
pathologically, even in cases without any clinical evidence of upper motor neuron 
involvement. The emergence of a close biological relation between ALS and frontotemporal 
dementia argues strongly in favour of a realignment of specialist expertise towards 
neurodegenerative and behavioural clinics, rather than concentration exclusively within the 
neuromuscular domain. And although the transgenic SOD1 model might have some value 
for understanding of the process of anterior horn cell degeneration, the extramotor 
manifestations of the disease, including significant cognitive and behavioural impairments, 
command attention that is not provided by existing animal models.
Further to such discussion, a causal primacy of lower motor neuron over upper motor neuron 
degeneration33 remains an issue of debate. Many of the initial pathological changes in 
models of ALS occur in the peripheral motor system, supporting a dying-back view of 
pathogenesis.34 However, ALS can also be viewed primarily as a disease of the upper motor 
neurons, or corticomotoneurons, which connect monosynaptically with anterior horn cells,
35 supported by the clinical observation that the oculomotor, abducens, and Onuf's motor 
nuclei, which all lack direct corticomotorneuron connections, are strikingly resistant to 
degeneration.
At the cortical level, premotor and motor regions might seem dominant, although frontal and 
anterior temporal regions, in addition to subcortical pathways, are key structures. Because 
motor planning, motor abstraction, emotional expression, and language, which are important 
aspects of human neocortical evolution, are all affected in ALS, these might hold clues to 
selective vulnerability and disease progression.36 As such, future studies need to consider 
ALS as a systems degeneration, rather than focusing on individual neuronal populations. 
Advanced MRI is uniquely able to study the brain at such a network level. Application of 
graph theory to structural data concerning white matter tract integrity,37 and independent 
component-type analysis to cerebral functional data,38 in parallel with detailed clinical and 
neuropsychological characterisation, offers a comprehensive in-vivo approach to probing 
disease activity in ALS.39 and 40
Can apparently sporadic ALS be inherited?
In populations of European origin, only 5–10% of patients with ALS report a family history 
of the disease (figure 2). It seems likely that there is a complex set of genetic determinants, 
each with potentially small but significant effect.15 Standard practice has been to reassure 
patients without an apparent family history of ALS. However, early studies of the C9orf72 
hexanucleotide repeat expansion suggest that the repeat expansion is also present in a 
sizeable minority of apparently sporadic cases, 19 and 41 and careful interrogation of 
kindreds of these patients, supported by death certification, shows increased rates of 
neurodegenerative conditions, most notably frontotemporal dementia. Such findings suggest 
that a family history of frontotemporal dementia, which might have been misclassified as 
Alzheimer's disease, must now be considered in a revised definition of familial ALS.
Furthermore, the definition of familial ALS is increasingly being recognised as inconsistent.
42 The definition is based on the presence of known disease in other members of a kindred. 
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In this context the size of the kindred also becomes important in determining heritability. 
Specifically, the presence of a small number of first-degree and second-degree relatives 
might erroneously lead to a diagnosis of sporadic ALS, whereas large extended kindreds 
might serve to increase the risk of a second case of ALS occurring by chance alone. Perhaps 
more reassuringly for patients with sporadic disease is the limited evidence obtained from 
clinic-based populations to date, suggesting that although there is approximately an eight-
fold increase to first-degree relatives of patients with ALS, the absolute increase in risk 
seemed to be very small in a follow-up study over 16 years.43
As with previous familial linkage to ALS, there appears to be incomplete penetrance of the 
C9orf72-related repeat expansion. Incomplete family histories and small family sizes might 
blur the distinction between sporadic and familial ALS further, suggesting that the 
reassuring figures for recurrence within offspring cannot be applied across all patients. 44 A 
clearer definition of familial ALS, followed by more extensive analyses of disease 
penetrance, might ultimately lead to a change in the routine counselling of patients. Whether 
the routine screening of all apparently sporadic cases of ALS for the known familial genetic 
abnormalities is the optimum approach at present, with the potential to register 
psychological harm, needs urgent debate.
The explosion in ALS genetics has challenged other long held doctrines relating to known 
genes of major effect, and evidence of an oligogenic cause in familial and sporadic ALS 
further compounds the problem of ALS heritability. Until recently, there had been an 
assumption that single genes of major effect with incomplete penetrance accounted for most 
cases of familial ALS. As each new ALS gene has been identified, ALS DNA banks have 
been screened to identify pathogenic variants in the new gene. DNA samples containing 
known variants are then excluded from further analyses. However, emerging evidence 
suggests a more complex genetic cause, in which the phenotypic variability might be due to 
a small number of genetic variants that co-occur with greater frequency than would be 
expected by chance. Recently described examples include FUS and TARDBP mutations in 
combination with ANG mutations and C9orf72 repeat expansions combined with TARDBP, 
SOD1, and FUS mutations. 45 If replicated, these findings will have important implications 
for the design and interpretation of ALS genetic studies. Whether this explanation accounts 
for the substantial phenotypic variations within C9orf72 kindreds remains to be established.
That the most important gene in ALS was identified with conventional genetic approaches, 
rather than the newer technologies of genome-wide association studies (GWAS) and next-
generation sequencing perhaps seems ironic. Whereas the chromosome 9 locus was 
identified a decade before its characterisation in sporadic ALS,46 the intronic repeat 
expansion could never have been identified with more modern sequencing methods because 
of the insensitivity of these technologies to detect very large intronic repeat expansions.
The history of GWAS in ALS started with fairly small studies (table 2) that initially had 
negative results or results that were not replicated in independent studies.47 and 50 Through 
international collaborations and data sharing, ongoing combined analysis of available data 
has now provided consistent results. Nevertheless, by contrast with other neurodegenerative 
diseases such as Parkinson's or Alzheimer's disease, the results of GWAS looking for 
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common variability have been disappointing in ALS, again suggesting that ALS is not one 
clinical entity, but is heterogeneous by nature. The best example of consistent GWAS results 
to date was the identification of the chromosome 9 locus, which appears aberrant in 5–8% of 
sporadic ALS. The larger GWAS effectively fine mapped the 9p locus from several 
megabases to a 110 kb region containing three genes, allowing the C9orf72 discovery. 
Nevertheless, continuing international collaboration will be needed to generate sample sizes 
that are comparable with other complex diseases, such as diabetes and inflammatory bowel 
disease. Also, the combined analysis of GWAS data of ALS with other neurodegenerative 
diseases (eg, Alzheimer's disease, Parkinson's disease, and frontotemporal dementia) will 
probably be of great value.
In view of the recent findings of intronic variation and repeated sequences in ALS, and the 
notion that rare genetic variants as opposed to the common genetic variants underlie 
pathogenesis, high-throughput exome sequencing and analysis of non-coding DNA by 
whole-genome sequencing in large samples are now needed to fully elucidate the genetic 
contribution to ALS pathogenesis.61 As has been the case for other diseases such as breast 
cancer, the discovery of one gene that affects a large minority of patients will probably help 
to identify other genes, since all datasets will now need to be reanalysed after removal of 
people with the C9orf72 expansion.
Is there a premorbid phenotype that reflects vulnerability to ALS?
Despite conflicting results regarding premorbid athleticism from case-control studies,62 and 
63 a clinical impression remains that patients who develop ALS frequently have a higher 
than average level of physical activity or fitness, perhaps best exemplified by the American 
baseball player Lou Gehrig. Whether the findings of reduced coronary artery disease 
premorbidly in patients with ALS,64 and a cardioprotective vascular profile of patients65 
and their first degree relatives,66 are significant in terms of premorbid fitness or athleticism 
remains uncertain. Several occupations likely to be linked with high physical activity and 
fitness have been associated with increased incidence of ALS, including professional 
footballers in Italy, the military, and manual workers.67 and 68 Separately, a lower than 
average body-mass index appears more commonly associated with ALS, linked to the 
observation of hypermetabolism that often develops in ALS. The biological processes 
accounting for these changes remain unclear. Mitochondrial impairment has been long 
considered as a possible pathogenic mechanism in neurodegeneration, and increasing the 
efficiency of oxidative phosphorylation remains one of the proposed mechanisms of the 
drug dexpramipexole, recently the subject of a phase 3 trial for ALS.69
It has been argued that physical activity might be harmful to a minority of the population 
who carry a complex genetic profile that adversely affects the metabolic response to 
vigorous muscle activity, including oxidative stress.70 Many patients with ALS specifically 
ask whether they can safely continue to exercise regularly without fear of accelerating their 
disease.70 Although low-grade exercise programmes might even have some benefit,71 there 
is no firm evidence that exercise exerts a harmful effect, although avoidance of very 
strenuous activity seems reasonable.
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An alternative formulation, which is not mutually exclusive, is that athleticism or fitness in 
patients with ALS is a reflection of a shared set of genetic determinants that predispose to 
neurodegeneration, without there being a direct causal link between ALS and exercise.62 In 
a cortically focused model of pathogenesis there might even be preferred loci for 
neurodegeneration,72 and 73 perhaps reflected in regional involvement,74 and an athletic 
profile might then also reflect a distinct motor system architecture. There would be an 
evolutionary advantage for a configuration associated with fitness, that is perhaps only 
rendered disadvantageous for a minority as a result of the relatively recent increases in life 
expectancy. Potential evolutionary trade-offs have been noted in other neurodegenerative 
disorders.75
When does ALS begin?
Longitudinal studies in presymptomatic individuals carrying pathogenic SOD1 mutations 
have shown apparently abrupt changes in both lower motor neuron loss 76 and the 
development of cortical hyperexcitability 77 within a year of symptom onset. Whether the 
nervous system of people who later develop ALS was normal immediately before disease 
onset or whether, like in Alzheimer's and Parkinson's diseases, a more prolonged 
presymptomatic phase of disease might have been detectable, seems uncertain. In support of 
a prolonged presymptomatic phase, changes in parenchymal metabolites (N-acetylaspartate 
in relation to choline and myoinositol) were detected in the spinal cord of presymptomatic 
individuals carrying pathological SOD1 mutations long before clinical disease onset. 78 The 
intriguing suggestion that the risk of ALS develops from factors operating at the time of 
conception or perhaps during early development warrants further consideration. 79
Detailed study of presymptomatic individuals carrying pathogenic mutations could provide 
unique insight into the nature of the earliest events before the tipping point of symptom 
onset. This pursuit is likely to be relevant to the long-term strategy of primary prevention, 
although these studies will be necessarily long term and costly. Although there might be 
ethical concerns associated with testing and studying of asymptomatic family members, a 
robust framework for this process has recently been established.80
How does ALS spread?
Typically, ALS has a striking focal clinical presentation, although this view must be 
interpreted with the understanding that most biological systems have a degree of redundancy 
and also in view of emerging data covering presymptomatic changes. For example, at least a 
third of muscle fibres have already been lost before clinical wasting occurs in ALS.81 
Nonetheless, post-mortem studies suggest that the pathological changes in ALS radiate from 
an area in which maximum upper motor neuron and lower motor neuron dysfunction 
aggregate together in the spinal region of first symptom onset.82 Spread of symptoms then 
appears to occur via an anatomically contiguous space within both upper motor neuron and 
lower motor neuron systems, although the rate might appear to differ within these two 
anatomical axes. Separately, a complete model of the ALS system failure requires 
incorporation of a third extramotor axis; namely, the substrate for cognitive and behavioural 
impairments.
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Irrespective of the basis for the regional pattern of involvement in ALS, important and 
unexplained differences remain in sex and age, particularly in relation to the site of disease 
onset. For example, respiratory-onset disease tends to be more prevalent in men,83 and a 
predilection for isolated corticobulbar disease has been noted in elderly women.84 Bulbar-
onset ALS is strikingly under-represented in young-onset patients,85 and the biological 
reasons for these phenomena require dedicated investigation.86 By contrast, regional onset 
could be purely stochastic82 or perhaps related to patterns of use or development.74 The 
convergence of upper motor neuron and lower motor neuron features might then reflect the 
topography of muscle innervation. Separately, there are also physiological differences 
between short and long axons that must be considered, including axonal membrane 
conductances and the Na+/K+ pump, the dysfunction of which might be relevant to 
pathogenesis.87
The development of advanced neuroimaging techniques has allowed novel assessment of 
structural and functional connections within the brain of patients with ALS that has further 
guided concepts about disease spread, individual susceptibility, and prognosis. Cortical 
correlates for regional symptoms can be shown with volumetric MRI.88 Neuronal 
connections are organised in networks and appear to have their own characteristics. 
Properties include the overall connectivity of the network, clustering of network nodes, the 
efficiency of the network, and the degree to which there are identifiable hubs.89 Recent 
investigations concerning functional connectivity in ALS have identified that patients with a 
strong connectedness of the motor network have a fast progression of disease, suggesting a 
potential role for assessment of the functional organisation of the motor network as a marker 
of disease progression.39 and 90 Positive correlation might also suggest patterns of disease 
spread along functional connections of the motor network in ALS, by contrast with the 
theory that ALS solely affects a fixed set of primary motor connections.40 These more 
widespread effects on the brain network suggest that focal damage in primary motor regions 
in ALS might ultimately manifest in connectivity disturbances elsewhere in the brain, with 
patterns of change potentially serving as biomarkers for disease progression. At the synaptic 
level, parallels have also been drawn for a prion-like spread of abnormal protein 
conformation and propagation of cellular toxicity in ALS,91 and 92 perhaps involving 
exosomes or autophagy.93
How can the course of ALS be predicted and the design of therapeutic clinical trials 
improved?
Prediction of the rate of progression in a heterogeneous disorder such as ALS has clear value 
in care-planning, but also in the assessment of potential therapeutic agents. Typical inclusion 
criteria for therapeutic trials have tended to be based on time from symptom onset (typically 
with a cutoff less than 3 years) and a minimum level of respiratory function as measured by 
vital capacity. Within only these criteria there will inevitably be a wide range of prognoses, 
thereby greatly reducing statistical power.
However, broad phenotypes with consistent prognostic patterns can be identified in a 
population-based context. These patterns include rapid decline in patients with respiratory-
onset disease,83 reduced survival in those with executive impairment,23 and slower 
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progression in those with upper motor neuron-predominant disease (consistent with the 
extreme example of primary lateral sclerosis).12 and 94 Consistent regional (generally 
contiguous) patterns of symptom spread are also recognisable,95, 96 and 97 and simple 
clinical parameters at diagnosis can allow robust stratification of prognosis for clinic-based 
patients.98 and 99 In view of these developments, a formal staging system for ALS has been 
proposed that attempts to better incorporate clinical phenotype.100 Stratification by rate of 
disease progression (time to spread to a new region) and degree of cognitive impairment, 
rather than the traditional divisions by site of onset or upper motor neuron- dominance 
versus lower motor neuron dominance, might yet prove more useful for future clinical trial 
enrolment.
At the individual patient level, prognostication soon after symptom onset remains difficult; 
for instance, it is difficult to distinguish typical bulbar-onset ALS (with progression to limb 
weakness) from a more atypical, isolated bulbar onset, which might remain isolated 
sometimes for several years before the involvement of other body regions (sometimes 
termed progressive bulbar palsy).101 Intrinsic heterogeneity among trial participants can 
obscure treatment effects that might be more obvious in specific clinical (or genetic) 
subgroups, and various strategies have been proposed to improve efficiency of clinical trials 
in ALS.102 Subgroup analysis of patients involved in previous clinical trials might have 
value; for example, some have suggested that riluzole could have an effect in delaying 
cognitive involvement.
Pending validation of the numerous and varied candidate biomarkers (summarised in panel 
2),103, 104 and 105 the revised ALS functional rating score (ALSFRS-R; panel 3) is a 
frequently used outcome measure in therapeutic trials.106 This score has good intrarater and 
inter-rater reliability, and prognostic value as a single measurement at the point of diagnosis 
as well as an indicator of the rate of change.107 However the slope of its decline might not 
be consistently linear, with deviations noted in early and late stages of the disease,108 so 
that statistical assumptions based on a linear model in trials involving patients early in their 
disease might be incorrect. Patient dropouts due to disease progression further complicate 
the design of ALS clinical trials, in addition to inherent and progressive problems for 
patients to attend the protocol centres, leading to potentially critical loss of statistical power. 
A method to combine survival and ALSFRS-R into one primary outcome measure was 
developed as the primary endpoint for the failed phase 3 trial of dexpramipexole.109 There 
is also increasing momentum to consider a further adjustment of the ALSFRS-R to include 
assessment of executive function, although further data are needed to validate available 
cognitive tools for ALS.
Motor unit number estimation, axonal excitability, electrical impedence myography, the 
neurophysiological index (NI), and cortical excitability all have potential as alternative 
outcome measures.105 The neurophysiological index has been shown to have good 
intrarater reliability and sensitivity to change in ALS, including the differentiation of fast 
and slow progressing patients.110 Longitudinal analysis supports incorporation of the NI 
into future therapeutic trials.111 More generally, that future trials must routinely incorporate 
candidate biomarkers if the historical reliance on survival as the primary outcome measure is 
to be overcome is widely agreed.
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Has the SOD1 mouse model outlived its usefulness?
The transgenic mouse model overexpressing SOD1 contains multiple copies of mutant 
human DNA. The model has been used extensively to dissect the likely pathogenic 
mechanisms of mutant SOD1 and to evaluate the possible benefits of new therapeutic 
agents. There has been a disappointing lack of drugs that meaningfully affect disease 
progression in the model and also in the translation of any modest disease-delaying benefits 
from mouse to human ALS. The repeated failures of phase 2 and 3 trials in human beings 
based on SOD1 mouse studies have led to calls for a reappraisal of the usefulness of the 
model.
Although the SOD1 mouse recapitulates several core clinical features of ALS—namely, a 
predictable and progressive loss of motor neurons, associated with muscle weakness 
commencing at approximately 90 days, and premature death—the pathological cascade 
plays out over a short period of time. 8 Therein might lie an inherent problem in the attempt 
to translate the results of therapeutic challenges to the human disease, in which symptoms do 
not emerge for several decades and where the disease develops through a combination of 
factors that are beyond genetic mutations and not captured by any model to date. Separately, 
therapeutic agents that have been tested and judged beneficial in the mouse model have been 
administered well before symptom onset.
A further failure of translation might partly relate to errors in early mouse studies, which 
were often inadequately powered and confounded by factors including differential effects of 
sex, failure to control for variations in copy number, differences in animal husbandry, and 
variability in mouse strain genetic backgrounds, leading to potentially erroneous 
conclusions. However, to address these issues, two recent workshops have generated 
guidelines that could largely resolve the confounders of early mouse studies, thereby 
rendering comparative analysis more robust.112, 113, 114 and 115
Proponents of the mouse model point out that translation from mouse to human being will 
always be imperfect because of cross-species differences in neuroanatomy, 
pharmacokinetics, and dynamics, as well as longevity. They also point to the reproducible 
murine phenotype and the similarities in neuropathology, including the early and selective 
degeneration of anterior horn cells. Conversely, some issues need to be further considered 
including the requirement for large copy numbers of mutant DNA to generate a phenotype, 
the absence of phenotype in the mouse with highly penetrant human mutations that lead to a 
severe phenotype in human beings (eg, the A4V mutation), and the observation that SOD1-
related ALS is not associated with TDP-43 inclusions—the pathological signature common 
to nearly all other forms of human ALS, including those associated with hexanucleotide 
repeat expansions in C9orf72. Although recent genetic advances have led to the 
development of new animal models based on transgenic TDP-43 and FUS mutants, no other 
model identified to date has recapitulated the clinical disease phenotype to the extent of the 
SOD1 mouse, despite the aforementioned caveats.
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Novel approaches to understanding of ALS pathogenesis
The cost of whole-genome sequencing is falling exponentially to a level that will soon make 
this approach feasible for a large number of patient samples. An internationally collaborative 
approach to sequence whole genomes from large cohorts of well characterised patients with 
ALS seems the next logical step. As a result, the characterisation of the genetic architecture 
of ALS might soon be complete, but is likely to be only the first step towards identification 
of key pathways amenable to therapeutic intervention. A limitation of the downstream 
transcriptomic approach is the difficulty in distinguishing primary (initiating) and secondary 
(responsive) changes in gene expression from the mass of data generated, although this 
approach holds promise.116 High-throughput proteome-wide studies are still beyond the 
horizon.
The bioinformatics task presented by the enormous volume and complexity of both genomic 
and RNA expression data has become the immediate challenge. It requires the neuroscience 
research community to engage those with the mathematical expertise needed to 
meaningfully interrogate and interpret such datasets, in conjunction with more sophisticated 
clinical phenotyping of patients.
Although animal modelling for ALS remains challenging, and rodent models have 
limitations, new models that engage technological developments hold promise for rapid 
assessment of therapeutic potential. Such models include the Caenorhabditis elegans worms, 
established for high-throughput, large-scale functional validation of candidate protective 
genes, including lines expressing forms of TDP-43 or FUS. 117, 118 and 119 Selection of 
nematode promoters can now also be used to express these proteins in neurons or more 
specifically only in motor neurons. In addition to the development of phenotypic assays, 
such studies could also unlock a holy grail in ALS research—the mechanism of disease 
spread at a molecular level.
The development of induced pluripotent stem cell technology offers an additional and 
potentially cost-effective approach as a platform for early modelling pathology and testing 
therapeutic candidates (so-called disease-in-a-dish). It marks a significant divergence from 
the traditional view of stem cells as a potential therapy for ALS.120 One of the major 
challenges will be to overcome the great heterogeneity across cell colonies, and to model the 
in-vivo network environment of such cells, which might be as important as any individual 
cellular dysfunction observed in isolation.121 Emerging themes might be common to other 
neurodegenerative disorders, in particular protein degradation pathways,6 and 122 making 
overlap in treatment strategy between ALS and other disorders increasingly likely.123
Conclusion
The enormous advances in scientific research during the past two decades have revealed the 
complexity of ALS pathogenesis (figure 3), which might have been underestimated at the 
time of the discovery of SOD1. Developments in molecular biology, particularly the 
discovery of C9orf72, when combined with new approaches in clinical neurophysiology and 
neuroimaging have accentuated rather than lessened the importance of detailed clinical 
assessment. The multiple pathogenic processes support the view of multiple routes to a 
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common endpoint of progressive upper motor neuron and lower motor neuron loss, which 
might mean that successful treatment will ultimately involve multiple targets.
The search for biomarkers in ALS is one of several research priorities (panel 4). Despite a 
large number of negative trials, ALS remains attractive to biotechnology companies with an 
array of approaches that are increasingly based on combating hypothesis-led mechanisms. 
Examples include small molecules to potentially interfere with protein aggregation, gene 
therapy to replace specific mutations, stem cell therapy to support glial as well as motor 
neuronal cells, and oligonucleotides to interfere with abnormal RNA processing. With 
improved understanding of the chemical structure of the drugs most likely to be effective, 
there is also potential for the repositioning of compounds held in pharmaceutical company 
drug libraries, abandoned for their original purposes, but in which extensive 
pharmacological and toxicity studies have often been completed.
Advances in the understanding of pathogenesis in ALS have occurred despite limitations in 
our understanding of fundamental aspects of the disorder and its taxonomy. These advances, 
coupled with the positive effects of the globalisation of scientific discussion and debate, will 
drive the emergence of the therapeutic era of ALS within the first half of this century.
Search strategy and selection criteria
We searched PubMed (1966, to Dec 31, 2012), Embase (1980, to Dec 31, 2012), and the 
Cochrane Library using the search terms “amyotrophic lateral sclerosis” or “motor neuron 
disease” in combination with “diagnosis”, “epidemiology”, “fronto-temporal dementia”, 
“imaging”, “neurophysiology”, “management”, and “neuroprotection”. Further articles were 
included from reference lists, review articles, and major textbook chapters. Abstracts and 
reports from relevant meetings were also included. The final reference list was generated on 
the basis of originality and relevance to the topics covered in this report. Emphasis was 
placed on publications from the past 5 years, but did not exclude commonly referenced and 
highly regarded older publications.
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Figure 1. Proposed mechanisms underlying neurodegeneration in ALS
Many of these pathways are mechanisms of cell death common to a range of neurological 
disorders, although in the case of amyotrophic lateral sclerosis (ALS), have been derived 
from studies undertaken predominantly using the SOD1 mouse model. Pathophysiological 
mechanisms involving more recent genetic discoveries, particularly the C9orf72 
hexanucleotide repeat expansion, have yet to be elucidated. Neurodegeneration in ALS 
might reflect combinations of glutamate excitoxicity, generation of free radicals, mutant 
SOD1 enzymes, along with mitochondrial dysfunction and disruption of axonal transport 
processes through accumulation of neurofilament intracellular aggregates. Mutations in 
several ALS-related genes are associated with the formation of intracellular aggregates, 
which appear harmful to neurons. Activation of microglia results in secretion of 
proinflammatory cytokines resulting in further toxicity. Failure of cytoplasmic mitochondria 
induces increased susceptibility to glutamate-mediated excitotoxicity, perturbations in motor 
neuronal energy production, and apoptosis. Mitochondrial dysfunction is associated with 
increased production of reactive oxygen species (ROS). Cytoplasmic aggregates of SOD1 
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might directly inhibit conductance of VDAC1, thereby reducing the supply of ADP to 
mitochondria for ATP generation. Δψ=mitochondrial membrane potential.
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Figure 2. The current macrogenetic landscape in ALS, highlighting the increasingly blurred 
boundary between familial and apparently sporadic disease
Only 5–10% of cases of amyotrophic lateral sclerosis (ALS) presenting to specialists report 
a positive family history of ALS or frontotemporal dementia (FTD). At least two-thirds of 
such cases can now be linked to one of four major genes, the largest group being those with 
expansions of the hexanucleotide repeat sequence in C9orf72. However, this expansion and 
mutations of the other genes identified are also detectable in a small but significant 
proportion of the 90–95% of cases of apparently sporadic ALS reporting no family history.
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Figure 3. Hypothesised sequence of events in the pathogenesis of the ALS syndrome
The early substrate for amyotrophic lateral sclerosis (ALS; A) is likely to involve genetic, 
developmental, and environmental factors. For most apparently sporadic cases, multiple 
genetic factors with small individual effects might in part affect development and maturation 
of the nervous system. This process might result in a motor system architecture that is more 
permissive to pathological changes later in life, for example. Environmental triggers might 
then operate on an already primed system. Several molecular mechanisms for 
neurodegeneration have been postulated (B), common themes including excitotoxicity (or 
loss of inhibitory neuronal buffering) and oxidative stress. A common endpoint seems to be 
protein misaggregation, in which several recent genetic discoveries have implicated 
abnormal RNA biology. ALS is a syndrome with cases showing variable involvement of 
upper and lower motor neurons, and extramotor cognitive impairment (C), in which there 
can be significant variation in rates of progression. Although there are extremes of relatively 
isolated involvement of each of these compartments, termed primary lateral sclerosis (PLS), 
progressive muscular atrophy (PMA), and frontotemporal dementia (FTD), all of these 
overlap with classic ALS on post-mortem neuropathological examination. A greater 
understanding of the nature of the apparent barriers between upper, lower, and extramotor 
neuronal populations might ultimate offer a disease-modifying strategy.
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Table 1
Genes (in order of discovery) associated with dominant mutations linked to adult-onset motor-predominant 
syndromes, showing the range of clinical phenotypes and principal neuropathological protein aggregates
Clinical involvement Neuropathological protein aggregates
SOD1 LMN, UMN Cytoplasmic inclusions of SOD1, or neurofilaments (eg, I113T); generally no TDP-43 aggregates
VAPB LMN, UMN Probable TDP-43 aggregates
ANG LMN, UMN, FTD TDP-43 aggregates
TARDBP LMN, UMN, FTD TDP-43 aggregates
FIG4 UMN Not known
FUS LMN, UMN, FTD FUS aggregates, no TDP-43 aggregates
OPTN LMN, UMN, FTD TDP-43 aggregation (Glu478Gly)
C9orf72 LMN, UMN, FTD TDP-43 aggregates, but also pathognomonic TDP-43-negative aggregates in cerebellar and hippocampal 
neurons (molecule currently unknown)
UBQLN2 LMN, UMN, FTD Ubiquilin-2, also TDP-43-positive and FUS-positive
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Table 2
Genome-wide association studies in amyotrophic lateral sclerosis
n (cases/controls) Genome-wide significant* 
result in or near gene
Independent 
samples or 
overlap
Remarks
Schymick et al 200747 276/271 None Overlap ..
Van Es et al 200748 461/450 None Overlap SNP in or near ITPR2 replicated 
in third phase of study
Cronin et al 200849 958/932 None Overlap ..
Van Es 200850 461/450 DPP6 Overlap Genome-wide significant in 
GWAS data plus replication 
cohort
Simpson et al 200951 781/702 ELP3 Unknown Different kind of genetic markers 
used (microsatellites)
Chio et al 200952 553/2338 None Overlap Original SNPs in or near DPP6, 
ITPR2, FGGY not replicated
Landers et al 200953 1821/2258 None Overlap ..
Van Es et al 200954 4855/14953 C9orf72 (9p21.2), UNC13A 
(19p13.3)
Overlap ..
Li et al 200955 58/52 None Independent SNP in or near DPP6 not 
replicated
Shatunov et al 201056 4312/8425 C9orf72 (9p21.2), UNC13A 
(19p13.3)
Overlap ..
Laaksovirta et al 201057 442/521 C9orf72 (9p21.2), SOD1 Independent ..
Iida et al 201158 92/233 None Independent Stepwise case-control association 
study, combined analysis 
genome-wide significant at SNP 
in or near ZNF512B; SNPs in or 
near DPP6, ITPR2, FGGY, 
UNC13A not replicated
Kwee et al 201259 442/348† None Independent Original SNP in DPP6 not 
replicated, other SNP in DPP6 
(p=0·0004) with same direction; 
ITPR2 not replicated; other SNP 
in ELP3 (p=0·0004); SNP in 
UNC13A, odds ratio 1·2 (same 
direction; p=0·04)
ALSGEN Consortium 201260 4243/5112 UNC13A (recessive model) Overlap No replication in samples 
independent from previous 
studies of DPP6 (69% power), 
ITPR2 (30% power), UNC13A 
(17% power)
Most replication attempts in these genome-wide association studies (GWAS) were underpowered because of a considerable overlap between 
samples included, so for these genes larger independent replication studies are needed to definitively assess their role. Additionally, when 
susceptibility genes also have a detrimental effect on survival, population-based cohorts will be needed that automatically will include patients with 
short survival in order to avoid underestimation of allele frequencies. Finally, this table clearly shows the need for combined analysis of available 
data to arrive at the so-called latest and greatest GWAS in amyotrophic lateral sclerosis, such as in the ALSGEN Consortium publication. Even 
more GWAS datasets are available now and will be in the near future. SNP=single nucleotide polymorphism.
*p<5·0×10–8.
†Also second cohort (n=5909).
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Panel 1
Diagnostic criteria for amyotrophic lateral sclerosis (ALS) derived from El Escorial13 and modified Airlie 
House criteria14
Diagnosis of ALS requires:
(1) The presence of: (a) evidence of lower motor neuron degeneration by clinical, electrophysiological, or neuropathological examination; (b) 
evidence of upper motor neuron degeneration by clinical examination; and (c) progression of the motor syndrome within a region or to other 
regions, as determined by history or examination; and
(2) The absence of: (a) electrophysiological and pathological evidence of other disease processes that might explain the signs of lower or upper 
motor neuron degeneration; and (b) neuroimaging evidence of other disease processes that might explain the observed clinical and 
electrophysiological signs.
El Escorial criteria
Definite ALS: upper and lower motor neuron signs in three regions.
Probable ALS: upper and lower motor neuron signs in at least two regions with upper motor neuron signs rostral to lower motor neuron signs.
Possible ALS: upper and lower motor neuron signs in one region, upper motor neuron signs alone in two or more regions, or lower motor 
neuron signs above upper motor neuron signs.
Suspected ALS: lower motor neuron signs only in two or more regions.
Airlie House (modified) criteria
Clinically definite ALS: clinical evidence alone of upper and lower motor neuron signs in three regions.
Clinically probable ALS: clinical evidence alone of upper and lower motor neuron signs in at least two regions with some upper motor neuron 
signs rostral to (above) the lower motor neuron signs.
Clinically probable–laboratory-supported ALS: clinical signs of upper and lower motor neuron dysfunction are in only one region, or upper 
motor neuron signs alone in one region with lower motor neuron signs defined by electromyography criteria in at least two limbs, together with 
proper application of neuroimaging and clinical laboratory protocols to exclude other causes.
Possible ALS: clinical signs of upper and lower motor neuron dysfunction in only one region, or upper motor neuron signs alone in two or more 
regions; or lower motor neuron signs rostral to upper motor neuron signs and the diagnosis of clinically probable-laboratory-supported ALS 
cannot be proven.
Suspected ALS: this category has been deleted from the revised El Escorial criteria.
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Panel 2
Leading candidate biomarkers in amyotrophic lateral sclerosis103, 104 and 105
CSF
• Neurofilaments
• Cystatin C
• TDP-43
• Neuroinflammatory molecules
Blood
• Neurofilaments
• TDP-43
• Neuroinflammatory molecules
MRI
• Reduced motor cortical density or thickness
• Fractional anisotropy of the corticospinal tract or corpus callosum
• Functional connectivity of the cortex
• Altered motor cortical metabolites
Neurophysiology
• Neurophysiological index
• Motor unit nerve estimation
• Electrical impedance myography
• Threshold-tracking transcranial magnetic stimulation
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Panel 3
Amyotrophic lateral sclerosis functional rating scale, revised106
1 Speech
    4 Normal speech
    3 Detectable disturbance
    2 Intelligible without repeating
    1 Speech with non-verbal communication
    0 Loss of useful speech
2 Salivation
    4 Normal
    3 Slight, but definite excess of saliva
    2 Moderate excessive saliva, minimum drooling
    1 Marked excessive of saliva, some drooling
    0 Marked drooling, needs constant tissue
3 Swallowing
    4 Normal eating habits
    3 Early eating problems, occasional choking
    2 Dietary consistency changes
    1 Needs supplemental tube feeding
    0 Nil orally
4 Handwriting
    4 Normal
    3 Slow or sloppy, all words legible
    2 Not all words legible
    1 Able to grip pen, but cannot write
    0 Unable to grip pen
5 Cutting food and handling utensils
    4 Normal
    3 Slow and clumsy, but no help needed
    2 Can cut most foods, although clumsy and needs some help
    1 Food must be cut by someone else
    0 Needs to be fed
6 Dressing and hygiene
    4 Normal
    3 Independent, but decreased efficiency
    2 Some help with closures and fasteners
    1 Provides minimum assistance to caregiver
    0 Unable to perform any task
7 Turning in bed
    4 Normal
    3 Slow and clumsy
    2 Can turn alone with difficulty
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    1 Can initiate but cannot turn or adjust sheets
    0 Total dependence
8 Walking
    4 Normal
    3 Early ambulation difficulties
    2 Walks with assistance
    1 Non-ambulatory, functional movement
    0 No purposeful leg movement
9 Climbing stairs
    4 Normal
    3 Slow
    2 Mild unsteadiness or fatigue
    1 Needs assistance
    0 Cannot do
10 Dyspnoea
    4 None
    3 Occurs when walking
    2 Occurs when eating, bathing, or dressing
    1 Occurs at rest
    0 Considerable difficulty
11 Orthopnoea
    4 None
    3 Some difficulty, does not routinely use more than two pillows
    2 Needs extra pillows to sleep
    1 Only sleeps sitting up
    0 Unable to sleep
12 Respiratory insufficiency
    4 None
    3 Intermittent use of non-invasive ventilation
    2 Continuous use of non-invasive ventilation at night
    1 Continuous use of non-invasive ventilation, day and night
    0 Mechanical ventilation via tracheostomy
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Panel 4
Priority areas for amyotrophic lateral sclerosis (ALS) research
• Understanding of the development of cortical and spinal motor neuron populations, their interaction with each other, and how it changes with 
normal ageing and in ALS
• Factors determining rate of disease progression
• Development of in-vitro and in-vivo models that accurately mimic ALS-related protein misfolding, aggregation, and accumulation
• Identification of the complete ALS-related genome
• Identification of the earliest, presymptomatic characteristics of ALS through the collaborative identification and study of relatives of patients 
with familial ALS
• Identification and standardisation of a biomarker for presymptomatic or early ALS and incorporation (with a view to validation) of at least one 
biomarker candidate in future therapeutic trials
• High-throughput compound screens in cellular and animal models of ALS (including zebrafish and worm models)
• Identification of possible environmental factors through large-scale international collaboration
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